The ad appears on the outside and inside of 450 MTA buses. Simultaneously, a similar ad jointly placed by OralCDx Laboratories and the American Dental Association is running on over 100 MTA buses.
The bus ads will be running until the end of November, leading into the Greater New York Dental Meeting, taking place at The Javits Center starting on November 28.
Oral cancer, one of the most disfiguring cancers, kills about as many Americans as melanoma and twice as many as cervical cancer. Very few cancers are preventable, and OralCDx is on a mission to let people know that oral cancer has recently joined the short list of preventable cancers. The effectiveness and accuracy of the BrushTest is referenced by both the National Cancer Institute and the ADA, and the test is used by over 30,000 dentists nationwide.
# # #
About the BrushTest
OralCDx Laboratories, a division of Oral Cancer Prevention International, Inc., is the worldwide, exclusive provider of the BrushTest. The BrushTest is used by dentists to help prevent oral cancer, a disease that kills as many Americans as melanoma, twice as many as cervical cancer, and is rising among women, young people and non-smokers. Well over 25% of those found to have oral cancer do not use tobacco or abuse alcohol. Recent studies have also shown a link between HPV and an increase in oral cancer.
The accuracy of the BrushTest was demonstrated in one of the largest studies in oral medicine ever conducted, performed at 35 academic centers in the U.S., involving nearly 1,000 patients. This study was published as the cover story of the Journal of the American Dental Association and earned OralCDx the ADA’s prestigious Seal of Acceptance.
For more information on the OralCDx BrushTest, call (877) 672-5722 or visit www.BrushTest.com.